Contrasting Spectral AI (MDAI) and Its Competitors

Spectral AI (NASDAQ:MDAI) is one of 229 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Spectral AI to related companies based on the strength of its earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Valuation & Earnings

This table compares Spectral AI and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spectral AI	$22.53 million	-$20.85 million	-1.14
Spectral AI Competitors	$1.07 billion	$10.77 million	1.61

Spectral AI’s competitors have higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

67.1% of Spectral AI shares are held by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 56.7% of Spectral AI shares are held by insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Spectral AI and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-89.85%	N/A	-104.64%
Spectral AI Competitors	-563.95%	-136.63%	-25.35%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Spectral AI and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	3	1	3.25
Spectral AI Competitors	1799	4755	8824	258	2.48

Spectral AI currently has a consensus target price of $4.50, indicating a potential upside of 194.12%. As a group, “Surgical & medical instruments” companies have a potential upside of 19.09%. Given Spectral AI’s stronger consensus rating and higher probable upside, analysts plainly believe Spectral AI is more favorable than its competitors.

Volatility & Risk

Spectral AI has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Spectral AI’s competitors have a beta of 0.55, indicating that their average share price is 45% less volatile than the S&P 500.

Summary

Spectral AI beats its competitors on 9 of the 13 factors compared.

Spectral AI Company Profile

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.